Caspian Journal of Internal Medicine
1
Caspian J Intern Med
Medical Sciences
http://caspjim.com
1
admin
2008-6164
2008-6172
8
10.22088/cjim
14
8888
13
en
jalali
1401
6
1
gregorian
2022
9
1
13
4
online
1
fulltext
en
Soluble urokinase plasminogen activator receptor (suPAR) in the emergency department: An update
Internal
Internal
Review Article
Review Article
<p align="justify" lang="en-US"><span style="font-size:14px;"><span style="font-family:Times New Roman;"><span style="line-height:14pt"><b><i><span style="color:blue">Background</span></i></b><i><span style="color:blue">:</span></i> The biomarker soluble urokinase plasminogen activator receptor (suPAR) is an indicator of inflammation which is increased in a variety of chronic and acute disease states. Its most promising application in the emergency setting is to aid in the prognostic stratification of patients by identifying those at high risk of deterioration. This is a narrative review of studies evaluating the use of suPAR<span style="font-size:9.0pt"></span></span><br>
<span style="line-height:14pt"><b><i><span style="color:blue">Methods:</span></i></b> We conducted a Medline search for studies on the use of suPAR in patients acutely admitted to the emergency department.</span><br>
<span style="line-height:14pt"><b><i><span style="color:blue">Results:</span></i></b> 25 original studies were included in the review. suPAR as a marker of inflammation has been used alone or combined to other inflammatory biomarkers in the assessment of patients suffering from various acute and chronic diseases in an emergency setting. As it is non-specific, it may increase in infectious disease, malignancy or acute coronary syndromes among other conditions, but quantitative suPAR levels correlate with disease severity. It may be useful for the identification of high risk patients regardless of underlying pathology.<b><i><span style="color:blue"></span></i></b></span><br>
<b><i><span style="color:blue">Conclusion</span></i></b><i><span style="color:blue">:</span></i> As the ideal biomarker in the emergency setting has not been identified yet, suPAR may be a promising addition to the established biomarkers for the initial assessment of patients in this setting. Additional research is necessary to evaluate the usefulness of suPAR guided management algorithms.</span></span></p>
suPAR, Biomarker, Emergency Department, Mortaliti, Infection, Sepsis
650
665
http://caspjim.com/browse.php?a_code=A-10-2156-1&slc_lang=en&sid=1
Dimitrios
Velissaris
dimitrisvelissaris@yahoo.com
100319475328460039777
100319475328460039777
No
Department of Internal Medicine, University Hospital of Patras, Patras, Greece
Nicholas
Zareifopoulos
nizareifopoulos@gmail.com
100319475328460039778
100319475328460039778
Yes
Department of Internal Medicine, University Hospital of Patras, Patras, Greece
Vasileios
Karamouzos
vkaramouzos@hotmail.com
100319475328460039779
100319475328460039779
No
Intensive Care Unit, University Hospital of Patras, Patras, Greece
Charalampos
Pierrakos
charalampos.pierrakos@chu-brugmann.be
100319475328460039780
100319475328460039780
No
Department of Intensive Care, Brugmann University Hospital, Université Libre de Bruxelles, Brussels, Belgium
Menelaos
Karanikolas
kmenelaos@yahoo.com
100319475328460039781
100319475328460039781
No
Department of Anesthesiology, Washington University School of Medicine, St. Louis, MO, USA